Back to Search
Start Over
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
- Source :
- Blood. 132:666-670
- Publication Year :
- 2018
- Publisher :
- American Society of Hematology, 2018.
-
Abstract
- TO THE EDITOR: Treatment of splenic marginal zone lymphoma (SMZL) is not standardized due to the lack of prospective randomized trials.[1][1][⇓][2][⇓][3][⇓][4][⇓][5][⇓][6][⇓][7][⇓][8][⇓][9][⇓][10][⇓][11][⇓][12]-[13][13] After our initial 2007 paper, we now present updated data
- Subjects :
- Adult
Male
medicine.medical_specialty
Immunology
Treatment outcome
Kaplan-Meier Estimate
Biochemistry
Gastroenterology
Drug Administration Schedule
Maintenance Chemotherapy
03 medical and health sciences
Remission induction
Antineoplastic Agents, Immunological
0302 clinical medicine
Internal medicine
medicine
Humans
Progression-free survival
Splenic marginal zone lymphoma
Aged
Retrospective Studies
Maintenance chemotherapy
Aged, 80 and over
business.industry
Splenic Neoplasms
Remission Induction
Follow up studies
Lymphoma, B-Cell, Marginal Zone
Cell Biology
Hematology
Middle Aged
medicine.disease
Progression-Free Survival
Lymphoma
Treatment Outcome
030220 oncology & carcinogenesis
Drug Evaluation
Female
Rituximab
business
Follow-Up Studies
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 132
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....9c3d1c1464258ae797dd8c7d0a8ec1ca